Delving into the Latest Updates on Berna Biotech Korea Corp with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Prophylactic vaccine	1

The primary objectives of this study were to demonstrate the non-inferiority of the recombinant hepatitis B vaccine Hepavax-Gene TF to the control vaccine in blocking the transmission of hepatitis B from hepatitis B-positive mothers to their children and in the seroprotection rate of newborns of hepatitis B-negative mothers one month after the completion of the vaccination schedule.

Start Date09 May 2011

Sponsor / Collaborator

Hangzhou Tigermed Consulting Co., Ltd.

[+1]

100 Clinical Results associated with Berna Biotech Korea Corp

Login to view more data

0 Patents (Medical) associated with Berna Biotech Korea Corp

Login to view more data

100 Deals associated with Berna Biotech Korea Corp

Login to view more data

100 Translational Medicine associated with Berna Biotech Korea Corp

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data